Low frequency of type-II aberrations in myeloid leukemia of down syndrome, underscoring the unique entity of this disease

Haematologica

Volumn 97, Issue 4, 2012, Pages 632-634

  Blink, Marjolein ^a   van den Heuvel Eibrink, Marry M ^a   de Haas, Valerie ^b   Klusmann, Jan Henning ^c   Hasle, Henrik ^d   Michel Zwaan, C ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aberrations; Down syndrome; ML; Type I; Type II

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE (NADP); ISOCITRATE DEHYDROGENASE 1; NUCLEOPHOSMIN; NUCLEOPORIN 98; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GENE MUTATION; HUMAN; INFANT; KARYOTYPE; LETTER; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; DOWN SYNDROME; FEMALE; HUMANS; INFANT; KARYOTYPE; LEUKEMIA, MYELOID; MALE; MUTATION;

EID: 84859467266     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.057505     Document Type: Letter

References (12)

1. Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo B, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011;96(10):1478-1487.
2. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532-1542.
3. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645-3656.
4. Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM, et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia. 2011;25(11):1704-1710.
5. Hollink IH, Feng Q, Danen-van Oorschot AA, Arentsen-Peters ST, Verboon LJ, Zhang P, et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia. 2011. [Epub ahead of print]
6. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2(7):429-436.
7. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5(1):11-20.
8. Chen J, Li Y, Doedens M, Wang P, Shago M, Dick JE, et al. Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome. Leukemia. 2010;24(5):1012-1017.
9. Hasle H, Lund B, Nyvold CG, Hokland P, Ostergaard M. WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. Leuk Res. 2006;30(5):543-546.
10. Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia. 2009;23(8):1472-1479.
11. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, et al. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. J Clin Oncol. 2010;28(28):e523-526; author reply e527-e528.
12. Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2011;29(6):704-711. PMCID: 3056655.